Biomea Fusion, Inc. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Biomea Fusion, Inc. (BMEA) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent of -23.60% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-24
- Biomea Fusion, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2025 was -23.60%.
- Biomea Fusion, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2024 was -28.80%.
- Biomea Fusion, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2023 was -34.60%.
- Biomea Fusion, Inc. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2022 was -21.50%.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 12 month |
|---|---|
| 2025-12-31 | -23.60% 10-K · filed 2026-03-24 |
| 2024-12-31 | -28.80% 10-K · filed 2026-03-24 |
| 2023-12-31 | -34.60% 10-K · filed 2026-03-24 |
| 2022-12-31 | -21.50% 10-K · filed 2025-03-31 |
| 2021-12-31 | -22.70% 10-K · filed 2024-03-28 |
| 2020-12-31 | -4.30% 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |